NIH to hold workshop on complementary and alternative medicine in cardiovascular, lung, and blood research

June 07, 2000

Alternative medicine practitioners and mainstream researchers will meet next week to exchange ideas, report on current research, and discuss ways to foster collaborative research in cardiovascular, lung, and blood research.

The workshop, "Complementary and Alternative Medicine in Cardiovascular, Lung, and Blood Research," will be held June 12 -- 13 in Lister Hill Auditorium (Building 38A) on the National Institutes of Health (NIH) campus in Bethesda, MD. The National Heart, Lung, and Blood Institute (NHLBI) and the National Center for Complementary and Alternative Medicine (NCCAM) of the NIH are co-sponsoring the 1-day event. The workshop will focus on five main areas of research -- herbal medicine, chelation therapy, mind/body (biofeedback), acupuncture, and general complementary and alternative medicine issues.

Sessions on these topics will be moderated by workshop co-chairs M. Eric Gershwin, M.D., of the University of California, Davis; John C. Longhurst, M.D., Ph.D., University of Calfornia, Irvine; and Kenneth Wu, M.D., Ph.D., University of Texas, Houston. NHLBI Director Claude Lenfant, M.D. and NCCAM Director Stephen E. Straus, M.D. are among the 20 speakers presenting. At the workshop's conclusion, attendees will develop recommendations for future research.
For more information, call the NHLBI Communications Office at 301-496-4236 or the NCCAM at 301-496-1712. The workshop agenda can be found online at:

NIH/National Heart, Lung and Blood Institute

Related Cardiovascular Articles from Brightsurf:

Changes by income level in cardiovascular disease in US
Researchers examined changes in how common cardiovascular disease was in the highest-income earners compared with the rest of the population in the United States between 1999 and 2016.

Meditation linked to lower cardiovascular risk
Meditation was linked to lower cardiovascular risk in a large database study by Veterans Affairs researchers and colleagues.

Framework on how to safely resume essential cardiovascular diagnostic and treatment care during the COVID-19 pandemic, from the AHA and 14 North American cardiovascular societies
The American Heart Association, together with 14 cardiovascular societies in North America, today issued joint guidance, 'Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership,' to outline a systematic, phased approach to safely reintroducing cardiovascular procedures for diagnosis and treatment during the COVID-19 pandemic.

Cardiovascular impairment in COVID-19
Anti-inflammatory therapies should be used to treat COVID-19 patients that are at risk of, or have developed, cardiovascular problems, recommend leading cardiologists from Beijing, China, who have detailed the different ways that COVID-19 could trigger serious inflammatory-related cardiovascular issues in patients.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

New insights into the effect of aging on cardiovascular disease
Aging adults are more likely to have - and die from - cardiovascular disease than their younger counterparts.

Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.

Premature death from cardiovascular disease
National data were used to examine changes from 2000 to 2015 in premature death (ages 25 to 64) from cardiovascular disease in the United States.

Vitamin D supplementation not associated with reduced cardiovascular events
This study, called a meta-analysis, combined the results of 21 randomized clinical trials with about 83,000 patients to look at whether vitamin D supplementation was associated with reduced risk of cardiovascular disease events such as heart attack or stroke.

Read More: Cardiovascular News and Cardiovascular Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to